Company intelligence / Profile preview

Apexigen America, Inc.

San Carlos, California, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

The lead program, sotigalimab (APX005M), a humanized agonist antibody targeting CD40, reached Phase 2 studies in solid tumors and was tested with chemotherapy, radiation, and immunotherapy combinations. Clinical and manufacturing activities focused on completing studies with this asset before acquisition[1].

Therapeutic areas: Oncology
Modalities: AntibodyMonoclonal antibodyHumanized monoclonal antibody
Industry: Biotech

Partnerships

Multiple, via licensing of APXiMAB-discovered antibodies (specific partners not detailed in results)

Beyond the preview

Go deeper on Apexigen America, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apexigen America, Inc..

Explore the full profile